Skip to main content

Drug Interactions between cyclosporine and st. john's wort

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

cycloSPORINE St. John's wort

Applies to: cyclosporine and st. john's wort

GENERALLY AVOID: Coadministration with St. John's wort may decrease the blood concentrations and pharmacologic effects of cyclosporine. The mechanism involves reduced absorption as well as accelerated clearance due to induction of intestinal P-glycoprotein drug efflux pumps and hepatic/intestinal CYP450 3A4 isoenzymes by constituents of St. John's wort. There have been case reports of transplant patients whose cyclosporine blood levels dropped significantly or became subtherapeutic following the initiation of St. John's wort. A few experienced acute rejection episodes. In a study of 11 renal transplant patients stabilized on cyclosporine, St. John's wort extract (600 mg daily for 14 days) decreased the dose-corrected peak blood concentration (Cmax), trough concentration (Cmin) and area under the concentration-time curve (AUC) of cyclosporine by 42%, 41% and 46%, respectively, compared to baseline. Cyclosporine doses increased from a median of 2.7 mg/kg/day at baseline to 4.2 mg/kg/day on day 12, and all patients required the first dose adjustment 3 days after initiation of St. John's wort. The reversal of these effects after discontinuation of St. John's wort took longer than 2 weeks in 8 of 11 patients.

MANAGEMENT: Given the risk of organ rejection associated with inadequate immunosuppressant blood levels, St. John's wort should preferably not be used in transplant patients treated with cyclosporine. Caution is advised if these agents are used together. Immunosuppressant blood levels should be closely monitored and the dosage(s) adjusted accordingly, particularly following initiation, discontinuation or change of dosage of St. John's wort in patients who are stabilized on their anti-rejection regimen. Transplant patients should be advised to consult their caregiver before using any alternative medicines.

References

  1. (2001) "Product Information. Rapamune (sirolimus)." Wyeth-Ayerst Laboratories
  2. Ernst E (1999) "Second thoughts about safety of St John's wort." Lancet, 354, p. 2014-6
  3. Fugh-Berman A (2000) "Herb-drug interactions." Lancet, 355, p. 134-8
  4. Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G (2000) "Acute heart transplant rejection due to Saint John's wort." Lancet, 355, p. 548-9
  5. Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH (2000) "St John's Wort: Effect on CYP3A4 activity." Clin Pharmacol Ther, 67, p. 451-7
  6. Breidenbach T, Hoffmann MW, Becker T, Schlitt H, Kiempnauer J (2000) "Drug interaction of St John's wort with ciclosporin." Lancet, 355, p. 1912
  7. Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR (2000) "Drug interaction between St. John's wort and cyclosporine." Ann Pharmacother, 34, p. 1013-6
  8. Karliova M, Treichel U, Malago M, Frilling A, Gerken G, Broelsch CE (2000) "Interaction of Hypericum perforatum (St. John's wort) with cyclosporin A metabolism in a patient after liver transplantation." J Hepatol, 33, p. 853-5
  9. Mai I, Krü, ger H, Budde K, Johne A, Brockmö, ller J, Neumayer HH, Roots I (2000) "Hazardous pharmacokinetic interaction of Saint John's wort (Hypericum perforatum) with the immunosuppressant cyclosporin." Int J Clin Pharm Therapeutics, 38, p. 500-2
  10. Barone GW, Gurley BJ, Ketel BL, AbulEzz SR (2001) "Herbal supplements: A potential for drug interactions in transplant recipients." Transplantation, 71, p. 239-41
  11. Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K (2000) "St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4." Clin Pharmacol Ther, 68, p. 598-604
  12. Ahmed SM, Banner NR, Dubrey SW (2001) "Low cyclosporin-A level due to Saint-John's-wort in heart transplant patients." J Heart Lung Transplant, 20, p. 795
  13. Moschella C, Jaber BL (2001) "Interaction between cyclosporine and Hypericum perforatum (St. John's wort) after organ transplantation." Am J Kidney Dis, 38, p. 1105-7
  14. Izzo AA, Ernst E (2001) "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs, 61, p. 2163-75
  15. Dresser GK, Schwarz UI, Wilkinson GR, Kim RB (2003) "Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects." Clin Pharmacol Ther, 73, p. 41-50
  16. Bauer S, Stormer E, Johne A, et al. (2003) "Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients." Br J Clin Pharmacol, 55, p. 203-11
View all 16 references

Switch to consumer interaction data

Drug and food interactions

Moderate

cycloSPORINE food

Applies to: cyclosporine

GENERALLY AVOID: Administration with grapefruit juice (compared to water or orange juice) has been shown to increase blood concentrations of cyclosporine with a relatively high degree of interpatient variability. The mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.

GENERALLY AVOID: Administration with red wine or purple grape juice may decrease blood concentrations of cyclosporine. In 12 healthy volunteers, 12 ounces total of a merlot consumed 15 minutes prior to and during cyclosporine administration (single 8 mg/kg dose of Sandimmune) decreased cyclosporine peak blood concentration (Cmax) and systemic exposure (AUC) by 38% and 30%, respectively, compared to water. The time to reach peak concentration (Tmax) doubled, and oral clearance increased 50%. Similarly, one study were 12 healthy patients were administered purple grape juice and a single dose of cyclosporine showed a 30% and a 36% decrease in cyclosporine systemic exposure (AUC) and peak blood concentration (Cmax), respectively. The exact mechanism of interaction is unknown but may involve decreased cyclosporine absorption.

MONITOR: Food has been found to have variable effects on the absorption of cyclosporine. There have been reports of impaired, unchanged, and enhanced absorption during administration with meals relative to the fasting state. The mechanisms are unclear. Some investigators found an association with the fat content of food. In one study, increased fat intake resulted in significantly increased cyclosporine bioavailability and clearance. However, the AUC and pharmacodynamics of cyclosporine were not significantly affected, thus clinical relevance of these findings may be minimal.

MANAGEMENT: Patients receiving cyclosporine therapy should be advised to either refrain from or avoid fluctuations in the consumption of grapefruits and grapefruit juice. Until more data are available, the consumption of red wine or purple grape juice should preferably be avoided or limited. All oral formulations of cyclosporine should be administered on a consistent schedule with regard to time of day and relation to meals so as to avoid large fluctuations in plasma drug levels.

References

  1. Honcharik N, Yatscoff RW, Jeffery JR, Rush DN (1991) "The effect of meal composition on cyclosporine absorption." Transplantation, 52, p. 1087-9
  2. Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ (1993) "Trough concentrations of cyclosporine in blood following administration with grapefruit juice." Br J Clin Pharmacol, 36, p. 457-9
  3. Bailey DG, Arnold JMO, Spence JD (1994) "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet, 26, p. 91-8
  4. Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF (1995) "The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients." Clin Pharmacol Ther, 57, p. 318-24
  5. (1995) "Grapefruit juice interactions with drugs." Med Lett Drugs Ther, 37, p. 73-4
  6. Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB (1995) "Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients." Clin Pharmacol Ther, 57, p. 425-33
  7. Yee GC, Stanley DL, Pessa LJ, et al. (1995) "Effect of grrapefruit juice on blood cyclosporin concentration." Lancet, 345, p. 955-6
  8. Ducharme MP, Warbasse LH, Edwards DJ (1995) "Disposition of intravenous and oral cyclosporine after administration with grapefruit juice." Clin Pharmacol Ther, 57, p. 485-91
  9. Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ (1997) "Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases." J Rheumatol, 24, p. 49-54
  10. Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG (1996) "Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients." Transplantation, 62, p. 123-5
  11. Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR (2000) "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther, 68, p. 468-77
  12. Tsunoda SM, Harris RZ, Christians U, et al. (2001) "Red wine decreases cyclosporine bioavailability." Clin Pharmacol Ther, 70, p. 462-7
  13. Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G (2010) "Influence of purple grape juice in cyclosporine availability." J Ren Nutr, 20, p. 309-13
View all 13 references

Switch to consumer interaction data

Moderate

St. John's wort food

Applies to: st. john's wort

GENERALLY AVOID: An isolated case report suggests that foods containing large amounts of tyramine may precipitate a hypertensive crisis in patients treated with St. John's wort. The mechanism of interaction is unknown, as St. John's wort is not thought to possess monoamine oxidase (MAO) inhibiting activity at concentrations achieved in vivo. The case patient was a 41-year-old man who had been taking St. John's wort for seven days prior to presentation at the emergency room with confusion and disorientation. The patient recalled last eating aged cheese and having a glass of red wine approximately 10 hours prior to admission. No other cause of delirium or hypertension could be identified. In addition, alcohol may potentiate some of the pharmacologic effects of St. John's wort. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

MANAGEMENT: Until further information is available, patients treated with St. John's wort should consider avoiding consumption of protein foods in which aging or breakdown of protein is used to increase flavor. These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, yogurt, papaya products, meat tenderizers, fava beans, protein extracts, and dietary supplements. Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well. Patients should also be advised to avoid or limit consumption of alcohol.

References

  1. Patel S, Robinson R, Burk M (2002) "Hypertensive crisis associated with St. John's Wort." Am J Med, 112, p. 507-8

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.